Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diagnosis Mandate Clear all
Completed No phase listed Observational

The COVID-19 PUI Reality Check (CPRC) Study

NCT04474288
View directory record Official record
Conditions
Covid19 Immunology
Interventions
SARS-CoV-2 antibody testing
Diagnostic Test
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 19, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

NCT00612274
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
tacrolimus, Sirolimus, Methotrexate
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 19, 2026, 2:41 PM EDT
Terminated Not applicable Interventional Results available

Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)

NCT04696354
View directory record Official record
Conditions
Venous Ulcer of Leg
Interventions
IVUS, Continued Compression Therapy/Stockings
Diagnostic Test · Other
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Darien, Connecticut • Winter Park, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 19, 2026, 2:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Antibiotics Prescription

NCT06436690
View directory record Official record
Conditions
Antimicrobial Resistance
Interventions
Diagnosis Mandate, Individualized Feedback
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 19, 2026, 2:41 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 19, 2026, 2:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 19, 2026, 2:41 PM EDT
Terminated Phase 3 Interventional

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

NCT04925960
View directory record Official record
Conditions
Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
Interventions
Epalrestat, Placebo
Drug
Lead sponsor
Maggie's Pearl, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 19, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Disseminating Organizational SBI Services at Trauma Centers

NCT00607620
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Dependence
Interventions
Brief Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 19, 2026, 2:41 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States

NCT07490431
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 19, 2026, 2:41 PM EDT